Revealing the novel effect of Jinghua Weikang capsule against the antibiotic resistance of Helicobacter pylori.

ABSTRACT:

Background

Helicobacter pylori (H. pylori) infects half of the human population globally. Eradication rates with triple or quadruple therapy have decreased owing to the increasing rate of antibiotic resistance. Jinghua Weikang capsule (JWC) is the first and most popular Chinese patent medicine approved by the state for the treatment of gastritis and peptic ulcers caused by H. pylori infection in China. Previous studies have found that JWC has a certain bactericidal effect on drug-resistant H. pylori and its major component, Chenopodium ambrosioides L. inhibits biofilm formation, but the mechanism remains unclear. This study focused on drug-resistant H. pylori and explored whether JWC could reverse drug resistance and its related mechanisms.

SUBMITTER: Jia X 

PROVIDER: S-EPMC9485998 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature